XLRN - Acceleron Pharma Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
47.07
+1.84 (+4.07%)
At close: 4:00PM EDT

47.07 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close45.23
Open44.86
Bid41.50 x 800
Ask49.00 x 800
Day's Range44.62 - 47.13
52 Week Range32.53 - 59.59
Volume321,480
Avg. Volume528,781
Market Cap2.433B
Beta (3Y Monthly)1.01
PE Ratio (TTM)N/A
EPS (TTM)-2.59
Earnings DateMay 6, 2019 - May 10, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est60.00
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of XLRN earnings conference call or presentation 27-Feb-19 10:00pm GMT

    Q4 2018 Acceleron Pharma Inc Earnings Call

  • Business Wire17 days ago

    Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Charcot-Marie-Tooth Disease

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to ACE-083, the Company’s locally-acting “Myostatin+” muscle agent, for the treatment of patients with Charcot-Marie-Tooth disease (CMT). “This formal designation aligns with our mission to develop therapies for patients with rare diseases of high unmet medical need,” said Robert K. Zeldin, M.D., Chief Medical Officer of Acceleron. “In clinical trials to date, treatment with ACE-083 has resulted in substantial increases in muscle volume in target muscles.

  • Acceleron Pharma Inc. (NASDAQ:XLRN): The Best Of Both Worlds
    Simply Wall St.20 days ago

    Acceleron Pharma Inc. (NASDAQ:XLRN): The Best Of Both Worlds

    Attractive stocks have exceptional fundamentals. In the case of Acceleron Pharma Inc. (NASDAQ:XLRN), there's is a company with strong financial health as well as an optimistic growth outlook. Below, I'veRead More...

  • Acceleron Pharma (XLRN) Q4 2018 Earnings Conference Call Transcript
    Motley Fool22 days ago

    Acceleron Pharma (XLRN) Q4 2018 Earnings Conference Call Transcript

    SQ earnings call for the period ending December 31, 2018

  • Business Wire22 days ago

    Acceleron Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

    - MEDALIST and BELIEVE Phase 3 trial presentations at the 60th American Society of Hematology Annual Meeting both selected for “Best of ASH” -

  • TheStreet.com23 days ago

    Acceleron Pharma Is Ready to Rally Ahead of Earnings

    Let's check the charts and indicators. In the daily bar chart of XLRN, below, I see a mixed picture with the indicators and chart patterns. Prices look like they have bottomed since the middle of December but the volume pattern and the daily On-Balance-Volume (OBV) line do not confirm a bottom that I could trust.

  • Is Acceleron Pharma a Buy?
    Motley Fool29 days ago

    Is Acceleron Pharma a Buy?

    The $2 billion development-stage company is about to file for regulatory approval of its lead drug candidate.

  • Earnings Preview: Acceleron Pharma (XLRN) Q4 Earnings Expected to Decline
    Zacks29 days ago

    Earnings Preview: Acceleron Pharma (XLRN) Q4 Earnings Expected to Decline

    Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wirelast month

    Acceleron to Webcast Fourth Quarter and Full Year 2018 Operating and Financial Results on February 27, 2019

    Acceleron Pharma Inc. (XLRN) today announced it will host a webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.m. EST to discuss its fourth quarter and full year 2018 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's website at www.acceleronpharma.com. The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.

  • Business Wirelast month

    Acceleron to Present at Two Upcoming Healthcare Investor Conferences

    Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will present at two upcoming healthcare investor conferences.

  • Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y
    Zacks2 months ago

    Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y

    Celgene (CELG) Q4 earnings beat estimates on robust revenues, driven by strong sales of Otezla and Revlimid.

  • Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings?
    Zacks2 months ago

    Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings?

    Investors are looking forward to Revlimid's performance and updates from the recently announced merger agreement when Celgene Corporation (CELG) reports Q4 results.

  • Barrons.com2 months ago

    Celgene Buys More of This Biotech Stock

    Acceleron is a biopharmaceutical company that Celgene is collaborating with to develop luspatercept, a potential treatment for blood disorders. Acceleron held a stock offering last week of 5.3 million shares, priced at $43 each, and noted that Celgene had indicated it intended to buy stock to maintain its percentage stake in the company. Celgene didn’t immediately respond to a request for comment.

  • GlobeNewswire2 months ago

    Consolidated Research: 2019 Summary Expectations for Marathon Petroleum, AMC Entertainment, JetBlue Airways, Acceleron Pharma, Natera, and AquaVenture — Fundamental Analysis, Key Performance Indications

    NEW YORK, Jan. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire2 months ago

    Acceleron Announces Pricing of Public Offering of Common Stock

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it has priced an underwritten public offering of 5,348,838 shares of common stock at a price to the public of $43.00 per share for gross proceeds of $230.0 million. In connection with this offering, Acceleron has granted the underwriters a 30-day option to purchase up to an additional 802,325 shares of common stock. Citigroup, J.P. Morgan and SVB Leerink are acting as joint book-runners for the offering.

  • Business Wire2 months ago

    Acceleron Announces Proposed Public Offering of Common Stock

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it intends to offer and sell, subject to market and other conditions, $200 million of its common stock in an underwritten public offering. As part of this offering, Acceleron intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. Citigroup, J.P. Morgan and SVB Leerink are acting as joint book-running managers for the offering.

  • Business Wire2 months ago

    Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the journal Blood has published results from the Phase 2 study of luspatercept in patients with red blood cell (RBC) transfusion-dependent and non-transfusion-dependent beta-thalassemia. Luspatercept is an investigational therapy that is part of a global collaboration between Acceleron and Celgene. In this open-label, Phase 2 study (a three-month initial stage followed by a five-year extension stage), patients were treated with luspatercept subcutaneously once every three weeks.

  • Celgene (CELG) Provides Guidance for 2019, Updates Pipeline
    Zacks2 months ago

    Celgene (CELG) Provides Guidance for 2019, Updates Pipeline

    Celgene (CELG) announces guidance for 2019, and other pipeline and regulatory updates.

  • Here's Why Acceleron Pharma Fell 17.7% in December
    Motley Fool2 months ago

    Here's Why Acceleron Pharma Fell 17.7% in December

    The promising pharma company ended the year on a sour note, but is still positioned for long-term success.

  • Business Wire3 months ago

    Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and Chief Executive Officer, will present an overview of the company along with its upcoming corporate priorities at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:00 p.m. PST / 5:00 p.m. EST in San Francisco, California.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool3 months ago

    3 Top Biotech Stocks to Buy Right Now

    The market's recent panic may be providing opportunities in this notoriously difficult sector.

  • How Financially Strong Is Acceleron Pharma Inc. (NASDAQ:XLRN)?
    Simply Wall St.3 months ago

    How Financially Strong Is Acceleron Pharma Inc. (NASDAQ:XLRN)?

    The direct benefit for Acceleron Pharma Inc. (NASDAQ:XLRN), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...

  • Is Acceleron Pharma Inc (XLRN) A Good Stock To Buy?
    Insider Monkey3 months ago

    Is Acceleron Pharma Inc (XLRN) A Good Stock To Buy?

    Is Acceleron Pharma Inc (NASDAQ:XLRN) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]

  • Business Wire3 months ago

    Acceleron Announces Luspatercept Phase 3 MEDALIST and BELIEVE Presentations Selected for “Best of ASH” by the American Society of Hematology

    Acceleron Pharma Inc. (XLRN) today announced that the presentations of the MEDALIST and BELIEVE Phase 3 trial results of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) and beta-thalassemia associated anemias, respectively, were selected for “Best of ASH” by the American Society of Hematology at its 60th Annual Meeting & Exposition in San Diego. Luspatercept is an investigational therapy that is part of a global collaboration between Acceleron and Celgene. “Having both the MEDALIST and BELIEVE trials included in the Best of ASH session at the close of the annual meeting is extraordinarily gratifying,” said Habib Dable, President and Chief Executive Officer of Acceleron.

  • Celgene (CELG) Announces Various Cancer Data at ASH 2018
    Zacks4 months ago

    Celgene (CELG) Announces Various Cancer Data at ASH 2018

    Celegne (CELG) presents data from several cancer studies at the annual meeting of American Society of Hematology (ASH).